Meet
Debbie Lucas

Debbie Lucas advises clients on value strategies, market access, and evidence generation.

Debbie leads efforts with life sciences companies, professional societies, quality improvement organizations, and healthcare providers related to the strategic collection and use of clinical data to improve patient care with a particular emphasis on electronic health data. Most recently she worked on an initiative that brought together the healthcare provider and EHR communities to design a module focused on childhood obesity to support improvements in healthcare via shared decision-making, care coordination, and self-management.

Prior to joining Avalere, Debbie was the director of Clinical Quality and Consulting at DocSite (later acquired by Covisint) and spent much of her career at GlaxoSmithKline.

Debbie has an MPH in epidemiology from the University of Michigan and a BS in biology from Baldwin-Wallace College. She was a member of the Commonwealth Fund’s Health Care Leaders Opinion Survey Panel.

Authored Content


Today, Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association published appropriate use criteria (AUC) to guide the use of lumbar puncture (LP) and cerebrospinal fluid (CSF) analysis for use in the diagnosis of Alzheimer’s disease.

The findings, published in The Journal of Endocrinology & Metabolism, will guide a pilot study to assess interventions to improve the identification and management of diabetes patients at high risk for hypoglycemia.

To help you organize the chaos of the ever-evolving quality measures landscape, we are pleased to introduce the Avalere Quality Measures Navigator (QMN).

Avalere published an article this week on ASCO's plan to launch CancerLinQ™.

Listen to Avalere's Debbie Lucas explain the complex world of quality measurement.

In the Calendar Year (CY) 2015 End Stage Renal Disease (ESRD) Prospective Payment System (PPS) final rule released on October 31, the Centers for Medicare & Medicaid Services (CMS) finalized a 2015 base per treatment rate of $239.43, up slightly from $239.02 in CY 2014.

Debbie Lucas from Avalere Health will discuss the emerging and complex quality landscape from the perspectives of healthcare stakeholders, including providers, health systems, health plans and others across the industry.

Listen to Debbie Lucas discuss how quality measurement can lead to improvements in the quality of care and the impact on providers.

The use of quality and performance measures in public reporting, value-based purchasing, and alternative payment models is altering clinical practice by providing incentives to improve quality measures performance and provide high-value care. Debbie Lucas helps many stakeholders seek to understand these measures, assess their business impacts, and use the information to guide decision-making.

In the Calendar Year (CY) 2015 End Stage Renal Disease (ESRD) Prospective Payment System (PPS) proposed rule released on July 2, CMS proposes a 2015 base per treatment rate of $239.33, up slightly from $239.02 in CY 2014.

On Feb. 21, CMS enhanced the Physician Compare website to include the addition of quality measures to indicate the performance achieved on a set number of specific metrics.